Abstract
Figures and Tables
Figure 1
Annual prevalence (A) and incidence (B) of atrial fibrillation (AF), 2006–2015, stratified by sex. Reproduced from Joung B et al. Korean Cir J 2018;48:1033-1080, according to the Creative Commons license [1]. a)P<0.05. b)P<0.001.
![jkma-62-265-g001](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-g001.jpg)
Figure 2
Annual incidence (A) and prevalence (B) of atrial fibrillation (AF), 2006–2015, stratified by age. Reproduced from Joung B et al. Korean Cir J 2018;48:1033-1080, according to the Creative Commons license [1]. a)P<0.05. b)P<0.001.
![jkma-62-265-g002](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-g002.jpg)
Figure 3
The projected prevalence of atrial fibrillation. Reproduced from Joung B et al. Korean Cir J 2018;48:1033-1080, according to the Creative Commons license [1].
![jkma-62-265-g003](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-g003.jpg)
Figure 4
Temporal trends of newly diagnosed atrial fibrillation patient by CHA2DS2-VASc (A) and HAS-BLED scores (B), 2006–2015. Reproduced from Joung B et al. Korean Cir J 2018;48:1033-1080, according to the Creative Commons license [1].
![jkma-62-265-g004](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-g004.jpg)
Figure 5
Temporal trends in 1-year adverse event rates of prevalent atrial fibrillation Korean population each year. HF, heart failure. a)P-value for trends <0.001. Reproduced from Joung B et al. Korean Cir J 2018;48:1033-1080, according to the Creative Commons license [1].
![jkma-62-265-g005](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-g005.jpg)
Figure 6
The basic concept of acute and chronic management of atrial fibrillation. OAC, oral anticoagulation therapy; VKA, vitamin K antagonist; TTR, time in therapeutic range; NOAC, non-vitamin K antagonist oral anticoagulant. Reproduced from Joung B et al. Korean Cir J 2018;48:1033-1080, according to the Creative Commons license [1].
![jkma-62-265-g006](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-g006.jpg)
Figure 7
Stroke prevention strategy in patients with atrial fibrillation. NOAC, non-vitamin K oral anticoagulant; OAC, oral anticoagulation. a)A congestive heart failure, hypertension, age ≥75 (doubled), diabetes mellitus, prior stroke or transient ischemic attack (doubled), vascular disease, age 65–74, female. Reproduced from Joung B et al. Korean Cir J 2018;48:1033-1080, according to the Creative Commons license [1].
![jkma-62-265-g007](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-g007.jpg)
Figure 8
Management of bleeding in patients taking oral anticoagulants. INR, international normalized ratio; IV, intravenous; NOAC, non-vitamin K oral anticoagulant. Adapted from Joung B et al. Korean Cir J 2018;48:1033-1080 [1].
![jkma-62-265-g008](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-g008.jpg)
Table 1
CHA2DS2-VASc scoring system
![jkma-62-265-i001](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-i001.jpg)
Adapted from Kirchhof P et al. Eur Heart J 2016;37:2893-2962 [11].
a)≥4 mm or ulcerative or mobile plaque.
Table 2
Indication and contraindication for NOAC in patient with atrial fibrillation
![jkma-62-265-i002](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-i002.jpg)
NOAC, non-vitamin K antagonist oral anticoagulant; PTAV, percutaneous transluminal aortic valvuloplasty; TAVI, transcatheter aortic valve implantation.
Adapted from Steffel J et al. Eur Heart J 2018;39:1330-1393 [13].
Table 3
Dose reduction of non-vitamin K antagonist oral anticoagulants
![jkma-62-265-i003](/upload/SynapseData/ArticleImage/0119jkma/jkma-62-265-i003.jpg)
Reproduced from Joung B et al. Korean Cir J 2018;48:1033-1080, according to the Creative Commons license [1]. bid, bis in die (twice a day); qd, quaque die (once a day).
a)Amiodarone, verapamil, dronedarone, etc. b)Coagulopathy, thrombocytopenia, platelet dysfunction, recent major trauma or biopsy, infective endocarditis. c)Should be used with caution in patients with significant renal impairment (creatinine clearance 15–29 mL/min).
References
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)
![crossref](/image/icon/bnr_ref_cross.gif)